Two Really Strategic & Important Market Releases are needed, forget the rest, unless it’s a ‘curve ball’ ………
Some of youse fellas seem to be having a damn good time with this thread and it is being done as a noble gesture to protect new and inexperienced investors in what is undoubtedly a spec stock - and I say “good on you” however, I think some posts are getting a bit too immoderate and effusive.
A Patent in India is of no consequence if there are no immediate plans to establish a market. But, it may be really important if there are developments that we are not aware of; I don’t think that is the case however, because Pacific Edge has advised they are focusing on the America market.
NEED TO SEE. Centres for Medicare & Medicaid Services sign up to
CxBladder.
The Centres for Medicare & Medicaid Services (
CMS) granted coverage for the Matritech BladderChek NMP22 in 2002; the test itself was quite cheap ($30-20) and was reimbursed by
CMS and other insurers for nearly full cost (then at $24). If
CMS accepts
CxBladder and we see this release, then that is full corroboration and acceptance of the tests utility and associated cost savings, this would be a major milestone and well worth shouting about.
NEED TO SEE. Veterans Administration Hospitals sign up to
CxBladder.
Dr. Giora Katz, was a Staff Urologist at the Department of Surgery-Urology Service, Lake City Veterans Administration Hospital and he ran a clinical trial of BladderChek NMP22 at twenty-three academic, private practice and veterans’ facilities in 10 states prospectively from September 2001 to May 2002. The results were good enough for the test to be slowly adopted by the Veterans Administration Hospitals; so again, if we see this release, that would also be full corroboration and acceptance of the tests utility and associated cost savings. (Woo Hoo).
AND THE REASON: NMP22 is only an adjunct to most tests only.
Attachment 7172